middle.news
Imugene Reports Third Response in BTKi-Resistant Lymphoma Cohort
9:39am on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Imugene Reports Third Response in BTKi-Resistant Lymphoma Cohort
9:39am on Monday 27th of July, 2026 AEST
Key Points
Third response achieved in concurrent BTKi cohort
Second Follicular Lymphoma patient shows partial response post-BTKi failure
CEO Leslie Chong resigns after nearly 11 years
Board initiates search for new CEO, with Executive Chairman overseeing transition
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE